Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Verrica Pharmaceuticals Inc
(NQ:
VRCA
)
7.240
-0.010 (-0.14%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Verrica Pharmaceuticals Inc
< Previous
1
2
3
Next >
Verrica Pharmaceuticals Announces Presentation of Lesion Clearance Data from an Ongoing Phase 2 Study of VP-315 for the Treatment of Basal Cell Carcinoma at the American Academy of Dermatology (AAD) 2023 Innovation Academy Meeting
August 10, 2023
From
Verrica Pharmaceuticals Inc.
Via
GlobeNewswire
Verrica Pharmaceuticals Reports Second Quarter 2023 Financial Results
August 08, 2023
From
Verrica Pharmaceuticals Inc.
Via
GlobeNewswire
Verrica Pharmaceuticals Announces Acceptance of Abstract Featuring Clinical Data of VP-315 for the Treatment of Basal Cell Carcinoma at the American Academy of Dermatology Association’s (AAD) 2023 Innovation Academy Meeting
August 03, 2023
Presentation to highlight the antitumor efficacy of VP-315 for the Treatment of Basal Cell Carcinoma (BCC) as determined by clinical and histological lesion clearance
From
Verrica Pharmaceuticals Inc.
Via
GlobeNewswire
Verrica Pharmaceuticals Announces Closing of $125 Million Debt Financing with OrbiMed
July 26, 2023
From
Verrica Pharmaceuticals Inc.
Via
GlobeNewswire
Following FDA Approval of YCANTH™ for the Treatment of Molluscum Contagiosum, Verrica Pharmaceuticals Enters into Non-Binding Term Sheet for up to $125 Million Debt Financing; Company to Host Conference Call and Webcast This Morning at 8:30 am ET
July 24, 2023
From
Verrica Pharmaceuticals Inc.
Via
GlobeNewswire
Verrica Pharmaceuticals Announces FDA Approval of YCANTH™ (cantharidin) topical solution as the First FDA approved Treatment of Pediatric and Adult Patients with Molluscum Contagiosum
July 21, 2023
From
Verrica Pharmaceuticals Inc.
Via
GlobeNewswire
Verrica Pharmaceuticals Announces Presentation at the Jefferies Healthcare Conference in New York
May 31, 2023
From
Verrica Pharmaceuticals Inc.
Via
GlobeNewswire
Verrica Pharmaceuticals Announces Presentation at the RBC Capital Markets Global Healthcare Conference
May 10, 2023
From
Verrica Pharmaceuticals Inc.
Via
GlobeNewswire
Verrica Pharmaceuticals Reports First Quarter 2023 Financial Results
May 09, 2023
From
Verrica Pharmaceuticals Inc.
Via
GlobeNewswire
Verrica Pharmaceuticals Announces Dosing of the First Patient in Part 2 of Phase 2 Study Evaluating VP-315 for the Treatment of Basal Cell Carcinoma
April 12, 2023
From
Verrica Pharmaceuticals Inc.
Via
GlobeNewswire
Verrica Pharmaceuticals Announces Presentation at the 22nd Annual Needham Virtual Healthcare Conference
April 11, 2023
From
Verrica Pharmaceuticals Inc.
Via
GlobeNewswire
Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2022 Financial Results
March 06, 2023
From
Verrica Pharmaceuticals Inc.
Via
GlobeNewswire
Verrica Pharmaceuticals Announces Participation at The Cowen 43rd Annual Health Care Conference
February 28, 2023
From
Verrica Pharmaceuticals Inc.
Via
GlobeNewswire
Verrica Pharmaceuticals Announces FDA Acceptance of Filing of Resubmitted NDA for VP-102 for the Treatment of Molluscum Contagiosum
February 27, 2023
From
Verrica Pharmaceuticals Inc.
Via
GlobeNewswire
Verrica Announces Pricing of $32.5 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
February 21, 2023
From
Verrica Pharmaceuticals Inc.
Via
GlobeNewswire
Verrica Pharmaceuticals Announces Resubmission of New Drug Application for VP-102 for the Treatment of Molluscum Contagiosum
January 24, 2023
From
Verrica Pharmaceuticals Inc.
Via
GlobeNewswire
Verrica Pharmaceuticals Announces the Successful Technology Transfer of Bulk Solution Manufacturing of VP-102 to Piramal Pharma Solutions
January 04, 2023
From
Verrica Pharmaceuticals Inc.
Via
GlobeNewswire
Verrica Pharmaceuticals Reports Third Quarter 2022 Financial Results
November 07, 2022
From
Verrica Pharmaceuticals Inc.
Via
GlobeNewswire
NASDAQ:VRCA Long Term Investor Alert: Investigation over Possible Wrongdoing at Verrica Pharmaceuticals Inc.
October 05, 2022
San Diego, CA -- (SBWIRE) -- 10/05/2022 -- An investigation was announced concerning potential breaches of fiduciary duties by certain directors of Verrica Pharmaceuticals Inc.
Via
SBWire
Deadline Alert - Bronstein, Gewirtz & Grossman, LLC Reminds Verrica Pharmaceuticals Inc. (VRCA) Investors of Class Action and Last Few Hours to Actively Participate
August 05, 2022
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Verrica Pharmaceuticals Inc. (VRCA)
August 04, 2022
From
The Law Offices of Frank R. Cruz
Via
Business Wire
INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in Verrica Pharmaceuticals Inc. with Losses of $100,000 to Contact the Firm
August 04, 2022
From
The Schall Law Firm
Via
Business Wire
VERRICA DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Verrica Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm
August 03, 2022
From
Bragar Eagel & Squire, P.C.
Via
Business Wire
INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Verrica Pharmaceuticals Inc. with Losses of $100,000 to Contact the Firm
August 03, 2022
From
The Schall Law Firm
Via
Business Wire
VRCA DEADLINE NOTICE: ROSEN, A LEADING LAW FIRM, Encourages Verrica Pharmaceuticals Inc. Investors with Losses Exceeding $100K to Secure Counsel Before Important August 5 Deadline in Securities Class Action - VRCA
July 31, 2022
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
Financial
Legal
GLOBALLY RECOGNIZED ROSEN LAW FIRM Encourages Wells Fargo & Company Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - WFC
July 01, 2022
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
Financial
Legal
Verrica Pharmaceuticals Inc. Investor News: Robbins LLP is Investigating Verrica Pharmaceuticals Inc. (VRCA) on Behalf of Shareholders
June 22, 2022
From
Robbins LLP
Via
Business Wire
NASDAQ:VRCA Investor Notice: Lawsuit Alleges Misleading Statements by Verrica Pharmaceuticals Inc.
June 21, 2022
San Diego, CA -- (SBWIRE) -- 06/21/2022 -- An investor, who purchased NASDAQ:VRCA shares, filed a lawsuit against Verrica Pharmaceuticals Inc over alleged violations of Federal Securities Laws.
Via
SBWire
NATIONALLY RANKED ROSEN LAW FIRM Encourages Verrica Pharmaceuticals Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - VRCA
June 20, 2022
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
Financial
Legal
Kirby McInerney LLP Reminds Investors That a Class Action Lawsuit Has Been Filed on Behalf of Verrica Pharmaceuticals, Inc. (VRCA) Investors and Encourages Investors to Contact the Firm Before August 5, 2022
June 17, 2022
From
Kirby McInerney LLP
Via
Business Wire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.